Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gastrointestinal Cancers
When treating esophageal cancer with post operative radiation, what, if any, are some strategies to minimize the risk of complications at the site of surgical anastomosis?
Related Questions
What adjuvant treatment approach would you recommend for a patient with early-stage MSI-high gastric cancer who received neoadjuvant ipilimumab (×2) and nivolumab (×6) per the NEONIPIGA regimen, followed by R0 resection with no pathologic response?
In an N+ rectal adenocarcinoma treated via PROSPECT with neoadjuvant FOLFOX with omission of CRT and no treatment response in the primary on pathology (ypN+), would you offer adjuvant chemotherapy or chemo-radiation?
What is your approach to pancreatic adenocarcinoma s/p surgery with N0/R0 disease and intermediate risk factors with regard to adjuvant chemo-radiation?
Would you dose escalate neoadjuvant radiotherapy for T3 and/or N+ rectal cancer in patients who are unwilling or unable to get chemotherapy?
What stomach constraint would you accept in abdominal reirradiation?
Would you recommend adjuvant radiotherapy in addition to chemotherapy in gastric adenocarcinoma s/p gastrectomy with a distal positive resection margin?
Would you hold HAI/ FUDR for SBRT of a residual liver metastasis following hepatic metastasectomy?
Do the results of recently presented ACCORD trial for EHC and gallbladder cancers have implications for your adjuvant treatment recommendations?
Given the results of PLATO anal cancer study, is 4140 cGy the new standard for early stage anal cancer?
Do you use different dose constraints for large bowel vs. small bowel?
